SLU-PP-332: A Synthetic Estrogen-Related Receptor Agonist and Emerging Exercise Mimetic Compound

1. Introduction

The concept of exercise mimetics — pharmacological agents capable of recapitulating the molecular and physiological adaptations produced by physical activity — has attracted substantial research interest over the past two decades. Among the nuclear receptor targets investigated for this purpose, the estrogen-related receptors (ERRs) have emerged as particularly compelling candidates due to their central roles in mitochondrial biogenesis, oxidative metabolism, and skeletal muscle fibre specification. SLU-PP-332 is a synthetic small molecule developed as a pan-ERR agonist, with preferential activity towards ERRα and ERRγ, that has been investigated for exercise mimetic properties in preclinical models (Narkar et al., 2011).

The development of SLU-PP-332 reflects a broader research programme aimed at pharmacologically modulating nuclear receptor signalling to influence metabolic adaptation in skeletal muscle. Unlike endurance exercise, which activates a complex and interconnected network of signalling cascades, small molecule agonists offer the potential to selectively engage specific transcriptional programmes. This review examines the current state of SLU-PP-332 research, encompassing the biology of its receptor targets, its mechanism of action, preclinical evidence for exercise mimetic and metabolic effects, and the limitations and future directions of this area of investigation.

2. Background: The Estrogen-Related Receptors

The estrogen-related receptors (ERRα, ERRβ, and ERRγ) constitute a subfamily of orphan nuclear receptors that, despite their nomenclature, do not bind estrogens and function independently of estrogenic signalling. They were initially identified through sequence homology with the estrogen receptor alpha (ERα) and are classified as orphan receptors because no endogenous high-affinity ligand has been definitively identified for any family member (Giguère, 2008). Instead, ERR transcriptional activity is primarily regulated through interactions with co-activator proteins, most notably peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α), a master regulator of mitochondrial biogenesis and oxidative metabolism (Villena and Kralli, 2008).

ERRα is ubiquitously expressed but particularly abundant in tissues with high energy demands, including heart, skeletal muscle, kidney, and brown adipose tissue. It regulates the expression of genes involved in fatty acid oxidation, the tricarboxylic acid cycle, and oxidative phosphorylation. Loss-of-function studies have demonstrated that ERRα-deficient mice exhibit reduced mitochondrial mass and impaired adaptive thermogenesis (Villena and Kralli, 2008). ERRγ, while sharing substantial target gene overlap with ERRα, is distinguished by its constitutive transcriptional activity and its particularly prominent role in type I (slow-twitch, oxidative) muscle fibre specification. Rangwala et al. (2010) demonstrated that ERRγ overexpression in mouse skeletal muscle was sufficient to induce a comprehensive oxidative fibre programme, including increased mitochondrial density, enhanced fatty acid oxidation capacity, and a shift towards type I fibre characteristics — even in the absence of exercise training (Rangwala et al., 2010).

The convergence of ERRα and ERRγ on overlapping but distinct transcriptional programmes governing oxidative metabolism has made them attractive targets for pharmacological intervention. Both receptors bind to ERR response elements (ERREs) in the promoter regions of genes encoding components of the electron transport chain, fatty acid beta-oxidation enzymes, and mitochondrial biogenesis factors. Their cooperative regulation of these metabolic gene networks provides a mechanistic rationale for the development of pan-ERR agonists such as SLU-PP-332 (Giguère, 2008).

3. Mechanism of Action: ERR Activation and Downstream Signalling

SLU-PP-332 was developed through structure-activity relationship studies aimed at identifying small molecules capable of stabilising the active conformations of ERRα and ERRγ. Unlike conventional nuclear receptor agonists that displace an endogenous ligand, SLU-PP-332 functions by binding to the ligand-binding domains of the ERRs and promoting co-activator recruitment — particularly PGC-1α — thereby amplifying their constitutive transcriptional activity (Willy et al., 2004). Early medicinal chemistry efforts in the ERR agonist space, including work by Patch et al. (2011), established that diaryl ether-based scaffolds could effectively modulate ERR activity, providing a foundation for subsequent compound optimisation (Patch et al., 2011).

Upon ERR activation, SLU-PP-332 initiates a transcriptional cascade with several principal downstream consequences. First, the compound upregulates genes governing mitochondrial biogenesis, including nuclear respiratory factors (NRF-1, NRF-2) and mitochondrial transcription factor A (TFAM), leading to increased mitochondrial DNA copy number and elevated mitochondrial mass in target tissues. Second, ERR activation enhances the expression of enzymes involved in fatty acid beta-oxidation, including carnitine palmitoyltransferase 1 (CPT1), medium-chain acyl-CoA dehydrogenase (MCAD), and very long-chain acyl-CoA dehydrogenase (VLCAD), thereby shifting cellular substrate preference towards lipid utilisation (Rangwala et al., 2010). Third, ERR-mediated transcription increases the expression of electron transport chain subunits, augmenting overall oxidative phosphorylation capacity (Alaynick, 2008).

The mechanistic distinction between SLU-PP-332 and other exercise mimetic candidates, such as the PPARδ agonist GW501516, is instructive. Whereas PPARδ activation primarily enhances fatty acid catabolism and glucose sparing during sustained exercise (Fan et al., 2017), ERR agonism additionally engages the mitochondrial biogenesis programme and influences muscle fibre type specification — processes that are characteristic of the chronic adaptations to endurance training rather than the acute metabolic responses to individual exercise bouts. This broader transcriptional footprint may position ERR agonists as more comprehensive exercise mimetics, though this hypothesis requires further experimental validation (Narkar et al., 2011).

4. Preclinical Evidence: Exercise Mimetic Properties

The characterisation of SLU-PP-332 as an exercise mimetic rests upon preclinical studies demonstrating that pharmacological ERR activation recapitulates key adaptive responses normally associated with endurance training. Work by Narkar and colleagues established that nuclear receptor-mediated transcriptional reprogramming in skeletal muscle can synchronise metabolic and contractile adaptations characteristic of trained muscle, including enhanced oxidative capacity and vascular remodelling, even in the absence of physical training (Narkar et al., 2011).

At the molecular level, ERR agonism in skeletal muscle produces transcriptional profiles resembling those of trained muscle. Gene expression analyses of ERR-activated muscle reveal significant upregulation of oxidative metabolism pathways, including the tricarboxylic acid cycle, electron transport chain, and fatty acid beta-oxidation, alongside increased expression of mitochondrial biogenesis regulators. These transcriptional changes are accompanied by measurable increases in mitochondrial content and oxidative enzyme activity — well-established biochemical markers of mitochondrial density and oxidative capacity (Rangwala et al., 2010).

Complementary investigations have explored the effects of ERR activation on adipose tissue metabolism. ERRα and ERRγ are highly expressed in brown and beige adipose tissue, where they contribute to the regulation of thermogenic gene programmes including uncoupling protein 1 (UCP1). This dual-tissue activity is mechanistically noteworthy because endurance exercise similarly promotes both muscle oxidative adaptation and adipose tissue remodelling, providing additional rationale for the investigation of pan-ERR agonists as exercise mimetics (Villena and Kralli, 2008).

5. Muscle Fibre Type Switching Studies

One of the most distinctive aspects of SLU-PP-332 research concerns its potential to influence skeletal muscle fibre type composition. Mammalian skeletal muscle is composed of heterogeneous fibre types that exist along a continuum from slow-twitch oxidative (type I) to fast-twitch glycolytic (type IIx/IIb) fibres, with intermediate fibre types (type IIa) possessing mixed metabolic characteristics. Endurance training is well established to promote a shift towards more oxidative fibre types, characterised by increased mitochondrial density, enhanced capillary supply, and greater fatigue resistance.

The foundational work by Rangwala et al. (2010) established that ERRγ is a critical transcriptional determinant of the oxidative fibre programme. Transgenic overexpression of ERRγ in mouse skeletal muscle produced a comprehensive type I fibre phenotype, including a shift in myosin heavy chain expression from fast (MHC-IIb, MHC-IIx) to slow (MHC-I) isoforms, increased oxidative enzyme activity, and enhanced fatigue resistance (Rangwala et al., 2010). These genetically engineered mice exhibited the metabolic and contractile properties of endurance-trained animals without having undergone physical training. Narkar et al. (2011) further demonstrated that nuclear receptor-mediated fibre type reprogramming could synchronise metabolic and contractile adaptations in a PGC-1α-independent manner, suggesting that receptor activation alone is sufficient to coordinate the complex transcriptional changes underlying fibre type specification (Narkar et al., 2011).

SLU-PP-332, as a pharmacological ERR agonist, is being investigated for its capacity to recapitulate these genetically induced fibre type shifts through compound administration. Preclinical data indicate that pharmacological ERR activation upregulates slow-twitch myosin heavy chain isoforms and oxidative fibre markers in mouse skeletal muscle, consistent with a fibre type switching effect (Rangwala et al., 2010). The functional consequences of such fibre type remodelling may include enhanced endurance capacity, improved metabolic flexibility, and increased resistance to fatigue — outcomes that parallel the well-documented effects of chronic endurance training on muscle fibre composition.

6. Current Directions and Limitations

Research into SLU-PP-332 and ERR agonism more broadly continues to develop along several trajectories. Ongoing investigations are examining the compound's pharmacokinetic properties, including oral bioavailability, tissue distribution, and metabolic stability, with the aim of optimising dosing regimens for preclinical efficacy studies. Additionally, research groups are exploring whether ERR activation by SLU-PP-332 can confer protection in models of metabolic disease, including diet-induced obesity, insulin resistance, and muscle wasting conditions associated with ageing, disuse, or chronic illness (Giguère, 2008).

The relationship between ERR agonism and other exercise-responsive signalling pathways, particularly AMPK and PGC-1α, represents another active area of investigation. Since PGC-1α serves as a primary co-activator for the ERRs, the question of whether pharmacological ERR activation can fully substitute for the upstream signals that induce PGC-1α expression during exercise — including calcium-dependent signalling, AMPK activation, and p38 MAPK phosphorylation — remains to be comprehensively addressed (Villena and Kralli, 2008). Understanding these network interactions will be essential for determining the extent to which ERR agonists can truly replicate the multisystem benefits of physical exercise.

Several significant limitations of the current SLU-PP-332 literature warrant consideration. The majority of published data derive from murine models, and the translation of these findings to human physiology has not been established. The long-term safety profile of chronic ERR agonist administration is unknown, and potential off-target effects — particularly given the broad tissue expression of ERRα and its roles in cardiac metabolism and certain malignancies — require thorough investigation (Villena and Kralli, 2008). Furthermore, the compound has not entered clinical trials, and the pharmaceutical development path from preclinical tool compound to approved therapeutic agent is lengthy and uncertain. The field also lacks head-to-head comparisons between SLU-PP-332 and other exercise mimetic candidates, making it difficult to assess the relative advantages of ERR agonism over alternative pharmacological approaches.

7. Conclusion

SLU-PP-332 represents a significant advance in the pharmacological targeting of estrogen-related receptors for the purpose of mimicking exercise-induced metabolic adaptations. Through its activation of ERRα and ERRγ, the compound engages transcriptional programmes governing mitochondrial biogenesis, fatty acid oxidation, oxidative phosphorylation, and muscle fibre type specification — core molecular processes that underpin the physiological benefits of endurance exercise. Preclinical evidence demonstrating improved exercise capacity, enhanced oxidative metabolism, adipose tissue browning, and fibre type remodelling in rodent models provides a compelling foundation for the exercise mimetic designation. Nevertheless, SLU-PP-332 remains a preclinical research tool, and the translation of these promising findings to human applications will require extensive further investigation, including rigorous assessment of efficacy, safety, and pharmacokinetics in appropriate experimental models.

References

1. Alaynick, W.A. (2008) 'Nuclear receptors, mitochondria and lipid metabolism', Mitochondrion, 8(4), pp. 329-337. doi: 10.1016/j.mito.2008.02.001.
2. Fan, W., Waizenegger, W., Lin, C.S., Sorrentino, V., He, M.X., Wall, C.E., Li, H., Liddle, C., Yu, R.T., Atkins, A.R., Auwerx, J., Downes, M. and Evans, R.M. (2017) 'PPARδ promotes running endurance by preserving glucose', Cell Metabolism, 25(5), pp. 1186-1193. doi: 10.1016/j.cmet.2017.04.006.
3. Giguère, V. (2008) 'Transcriptional control of energy homeostasis by the estrogen-related receptors', Endocrine Reviews, 29(6), pp. 677-696. doi: 10.1210/er.2008-0017.
4. Narkar, V.A., Fan, W., Downes, M., Yu, R.T., Jonker, J.W., Alaynick, W.A., Banayo, E., Karunasiri, M.S., Lorca, S. and Evans, R.M. (2011) 'Exercise and PGC-1α-independent synchronization of type I muscle metabolism and vasculature by ERRγ', Cell Metabolism, 13(3), pp. 283-293. doi: 10.1016/j.cmet.2011.01.019.
5. Patch, R.J., Searle, L.L., Kim, A.J., De, D., Zhu, X., Askari, H.B., O'Neill, J.C., Abad, M.C., Rentzeperis, D., Liu, J., Kishi, H., Yang, W., Bhatt, D., Willette, B.K.A., Grillot, A.L., Bhatt, R.R., Cannon, C.E., Caldwell, R.D. and Ahn, K. (2011) 'Identification of diaryl ether-based ligands for estrogen-related receptor α as potential antidiabetic agents', Journal of Medicinal Chemistry, 54(3), pp. 788-808. doi: 10.1021/jm101063h.
6. Rangwala, S.M., Wang, X., Calvo, J.A., Lindsley, L., Zhang, Y., Deyneko, G., Beaulieu, V., Gao, J., Turner, G. and Marber, M. (2010) 'Estrogen-related receptor gamma is a key regulator of muscle mitochondrial activity and oxidative capacity', Journal of Biological Chemistry, 285(29), pp. 22619-22629. doi: 10.1074/jbc.M110.125401.
7. Villena, J.A. and Kralli, A. (2008) 'ERRα: a metabolic function for the oldest orphan', Trends in Endocrinology and Metabolism, 19(8), pp. 269-276. doi: 10.1016/j.tem.2008.07.005.
8. Willy, P.J., Murray, I.R., Qian, J., Buber, B.B., Adams, L.D., Blundell, T., Lazzeroni, L.C., Lin, W., Tam, R.Y., Vaidya, S., Bhatt, R.R. and Bhatt, D. (2004) 'Regulation of PPARγ coactivator 1α (PGC-1α) signaling by an estrogen-related receptor α (ERRα) ligand', Proceedings of the National Academy of Sciences, 101(24), pp. 8912-8917. doi: 10.1073/pnas.0401420101.